Novavax, Inc. (NVAX): Price and Financial Metrics

Novavax, Inc. (NVAX): $16.52

-0.33 (-1.96%)

POWR Rating

Component Grades













Add NVAX to Watchlist
Sign Up

Industry: Biotech



in industry


  • NVAX scores best on the Growth dimension, with a Growth rank ahead of 98.35% of US stocks.
  • The strongest trend for NVAX is in Growth, which has been heading down over the past 179 days.
  • NVAX's current lowest rank is in the Sentiment metric (where it is better than 0.34% of US stocks).

NVAX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for NVAX is -3.26 -- better than only 3.52% of US stocks.
  • Of note is the ratio of NOVAVAX INC's sales and general administrative expense to its total operating expenses; just 6.55% of US stocks have a lower such ratio.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -8.12 for NOVAVAX INC; that's greater than it is for merely 2.43% of US stocks.
  • Stocks that are quantitatively similar to NVAX, based on their financial statements, market capitalization, and price volatility, are GRNA, HGEN, ATHX, KZIA, and CNCE.
  • NVAX's SEC filings can be seen here. And to visit NOVAVAX INC's official web site, go to

NVAX Valuation Summary

  • In comparison to the median Healthcare stock, NVAX's price/sales ratio is 65% lower, now standing at 0.7.
  • NVAX's price/earnings ratio has moved up 3.5 over the prior 243 months.

Below are key valuation metrics over time for NVAX.

Stock Date P/S P/B P/E EV/EBIT
NVAX 2022-11-25 0.7 -2.3 -1.0 -0.3
NVAX 2022-11-23 0.7 -2.4 -1.0 -0.4
NVAX 2022-11-22 0.7 -2.3 -1.0 -0.4
NVAX 2022-11-21 0.8 -2.6 -1.1 -0.5
NVAX 2022-11-18 0.8 -2.7 -1.2 -0.5
NVAX 2022-11-17 0.9 -2.9 -1.2 -0.6

NVAX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 58.8%.
  • Its 3 year revenue growth rate is now at 4802.79%.
  • Its 2 year cash and equivalents growth rate is now at 745.36%.
NVAX's revenue has moved up $1,828,011,000 over the prior 33 months.

The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,846.673 -640.529 -1,321.974
2022-06-30 1,290.94 -743.964 -1,475.792
2022-03-31 1,403.032 -428.649 -1,317.624
2021-12-31 1,146.29 322.946 -1,743.751
2021-09-30 1,203.749 536.786 -1,075.031
2021-06-30 1,181.929 672.432 -949.91

NVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVAX has a Quality Grade of C, ranking ahead of 58.82% of graded US stocks.
  • NVAX's asset turnover comes in at 0.6 -- ranking 60th of 680 Pharmaceutical Products stocks.
  • GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.

The table below shows NVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.600 1 -14.595
2021-03-31 0.606 1 -1.737
2020-12-31 0.502 1 -0.781
2020-09-30 0.345 1 -0.602
2020-06-30 0.126 1 -0.222
2020-03-31 0.084 1 -0.295

NVAX Price Target

For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $264.20 Average Broker Recommendation 1.58 (Moderate Buy)

NVAX Stock Price Chart Interactive Chart >

Price chart for NVAX

NVAX Price/Volume Stats

Current price $16.52 52-week high $236.50
Prev. close $16.85 52-week low $15.53
Day low $15.53 Volume 6,191,600
Day high $16.55 Avg. volume 5,723,022
50-day MA $19.61 Dividend yield N/A
200-day MA $46.13 Market Cap 1.30B

Novavax, Inc. (NVAX) Company Bio

Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.

NVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream

Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

Is Novavax Stock A Buy On Its Massive Sales Beat Despite Unexpected Losses?

Is Novavax stock a buy after the Covid vaccine maker handily beat third-quarter sales estimates? Is NVAX stock a buy right now?

Yahoo | November 29, 2022

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescen

Yahoo | November 29, 2022

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

Yahoo | November 28, 2022

Is Novavax Stock a Buy Now?

Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Importantly, Gavi has paid Novavax $700 million in the last two years, and its $350 million payment in 2021 accounted for a large fraction of the biotech's $1.1 billion in total revenue for the year.

Yahoo | November 26, 2022

3 Potentially Explosive Stocks to Buy Before 2023

It's been a difficult year for stocks (and investors) in general. But certain stocks have had a particularly trying time. These companies faced specific challenges -- and that's sent their shares tumbling further than the general market.

Yahoo | November 26, 2022

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo -18.10%
3-mo -45.64%
6-mo -65.25%
1-year -89.71%
3-year 238.52%
5-year -42.24%
YTD -88.45%
2021 28.30%
2020 2,701.76%
2019 -89.18%
2018 48.39%
2017 -1.59%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6095 seconds.